Table 1

 Summary of patient demographics and clinical and functional assessments at baseline, week 12 after treatment, and weeks 14–19 (2–7 weeks after stopping treatment)*

BaselineWeek 12Weeks 14–19
*Except where indicated otherwise, values are the median (range); †significant values (p<0.05) by Wilcoxon’s matched pairs signed rank test.
CRP, C reactive protein; ESR, erythrocyte sedimentation rate; EMS, early morning stiffness; VAS, visual analogue scale; BASFI, Bath Ankylosing Spondylitis Functional Index; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; ASQoL, Ankylosing Spondylitis Quality of Life questionnaire.
Age (years), mean (range)45 (31–58)
Men (%)100
Disease duration (years), mean (range)18 (3–33)
HLA-B27 positive (%)87.5
CRP (mg/l)31 (14–65)17 (6–47)†240 (140–450)
ESR (mm/1st h)19 (13–66)15 (5–58)†22 (8–98)†
EMS (min)60 (15–120)20 (5–120)60 (20–180)†
VAS scores (0–100 mm scale)
    Night back pain68 (40–91)35 (8–94)†59 (24–94)
    Total back pain65 (44–91)41 (5–85)63 (40–95)†
    Patient’s global assessment67 (42–91)41 (3–80)74 (28–96)†
BASFI score (0–10)5.88 (2.81–7.49)3.63 (0.63–8.24)†6.13 (3.52–8.74)†
BASDAI score (0–10)5.63 (3.83–7.8)3.48 (0.48–7.68)†6.55 (2.82–8.27)†
ASQoL score (0–18)12 (5–16)8 (0–15)†12 (5–17)†